Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Hepatitis C

  Free Subscription


2 Am J Gastroenterol
1 Eur J Gastroenterol Hepatol
1 Gastroenterology
1 Hepatology
2 J Hepatol
1 J Med Virol
7 J Viral Hepat
1 J Virol
1 Lancet
2 PLoS One
1 Virology

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Gastroenterol

  1. SOLLIMA S, Milazzo L, Antinori S, Galli M, et al
    Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV Eradication.
    Am J Gastroenterol. 2017;112:1753-1754.
    PubMed     Text format    

  2. LIU X, Shen JJ, Lee JL, Yoo JW, et al
    Cost-Effective but Unaffordable and Unequal Hepatitis C Treatment in the US.
    Am J Gastroenterol. 2017;112:1749.
    PubMed     Text format    

    Eur J Gastroenterol Hepatol

  3. MOSER S, Kozbial K, Laferl H, Schutz A, et al
    Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027.
    PubMed     Text format     Abstract available


  4. DEBES JD, van Tilborg M, Groothuismink ZMA, Hansen BE, et al
    Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 1. pii: S0016-5085(17)36295.
    PubMed     Text format     Abstract available


  5. SIKAVI C, Chen PH, Lee AD, Saab EG, et al
    Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29642.
    PubMed     Text format     Abstract available

    J Hepatol

  6. CARRIERI MP, Protopopescu C, Marcellin F, Wittkop L, et al
    The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32406.
    PubMed     Text format    

  7. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available

    J Med Virol

  8. ISHIGAMI M, Hayashi K, Honda T, Kuzuya T, et al
    Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    J Med Virol. 2017 Nov 7. doi: 10.1002/jmv.24978.
    PubMed     Text format     Abstract available

    J Viral Hepat

  9. CHAN HLY, Chen CJ, Omede O, Al Qamish J, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:25-43.
    PubMed     Text format     Abstract available

  10. DORE GJ, Hatzakis A, Negro F, Waked I, et al
    Estimating HCV disease burden-volume 4 (editorial).
    J Viral Hepat. 2017;24 Suppl 2:4-7.
    PubMed     Text format     Abstract available

  11. MAAROUFI A, Vince A, Himatt SM, Mohamed R, et al
    Historical epidemiology of hepatitis C virus in select countries-volume 4.
    J Viral Hepat. 2017;24 Suppl 2:8-24.
    PubMed     Text format     Abstract available

  12. CHEN DS, Hamoudi W, Mustapha B, Layden J, et al
    Strategies to manage hepatitis C virus infection disease burden-Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:44-63.
    PubMed     Text format     Abstract available

  13. SALMON-CERON D, Mondelli MU, Maticic M, Arends JE, et al
    The success of HCV cure: every rose has its thorn.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12823.
    PubMed     Text format     Abstract available

  14. BHARDWAJ N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, et al
    Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825.
    PubMed     Text format     Abstract available

  15. VUKOTIC R, Di Donato R, Conti F, Scuteri A, et al
    Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
    J Viral Hepat. 2017;24:13-16.
    PubMed     Text format     Abstract available

    J Virol

  16. SCHWEITZER CJ, Zhang F, Boyer A, Valdez K, et al
    N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly.
    J Virol. 2017 Nov 8. pii: JVI.01166-17. doi: 10.1128/JVI.01166.
    PubMed     Text format     Abstract available


  17. GARTNER C, Miller A, Bonevski B
    Extending survival for people with hepatitis C using tobacco dependence treatment.
    Lancet. 2017;390:2033.
    PubMed     Text format    

    PLoS One

  18. LOGGI E, Galli S, Vitale G, Di Donato R, et al
    Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
    PLoS One. 2017;12:e0187755.
    PubMed     Text format     Abstract available

  19. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    PubMed     Text format     Abstract available


  20. MANICKAM C, Martinot AJ, Jones RA, Varner V, et al
    Hepatic immunopathology during occult hepacivirus re-infection.
    Virology. 2017;512:48-55.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.